Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10065


The purpose of this study is to use a new imaging drug called 11C-choline that is used with a PET/CT scan to see prostate cancer when it cannot be seen well on other scans, such as bone scans, CT or MRI.


Inclusion Criteria: - Patient must have biopsy-proven adenocarcinoma of the prostate initially treated with curative intent (surgery and radiation therapy are most common treatments but other treatments are also eligible). - Biochemical recurrence defined as any of the following: 1. PSA ≥ 0.2 ng/mL in at least two sequential tests for patients treated with surgery. 2. PSA ≥ 0.2 ng/mL above the post therapy nadir for patients treated with radiation therapy, brachytherapy or cryotherapy. 3. PSA ≥ 0.2 ng/ml above the most recent therapy nadir for patients who have received additional treatment in the recurrent setting - Patient must have undergone standard-of-care restaging that does not clearly identify site(s) of active disease, or such prior studies must show equivocal findings for which further work-up is considered necessary to make clinical decision. Standard staging examinations may include one or more of the following: CT or MRI, bone imaging (either Tc-99m bisphosphonate scintigraphy MDP or F-18 sodium fluoride PET), FDG PET, or In-111 capromab pendetide scintigraphy no older than 3 months of consent date. - Age ≥ 18 years. - Patient must be able to tolerate PET/CT imaging. - Patient must be able to understand and willing to sign a written informed consent document. Exclusion Criteria: - Patient must not have claustrophobia that would preclude PET/CT imaging or other contraindications to CT imaging.



Primary Contact:

Principal Investigator
Heiko Schӧder, MD
Memorial Sloan Kettering Cancer Center

Heiko Schӧder, MD
Phone: 212-639-2079

Backup Contact:

Wolfgang Weber, MD
Phone: 212-639-7373

Location Contact:

New York, New York 10065
United States

Heiko Schoder, MD
Phone: 212-639-2079

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.